Nektar Therapeutics buy HC Wainwright
Start price
25.02.25
/
50%
€0.80
Target price
25.02.26
€6.19
Performance (%)
-27.14%
Price
06.06.25
€0.58
Summary
This prediction is currently active. The prediction for Nektar Therapeutics disappoints with a performance of -27.14%. This prediction currently runs until 25.02.26. The prediction end date can be changed by HC_Wainwright at any time. HC_Wainwright has 50% into this predictionNektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Nektar Therapeutics | - | - |
| iShares Core DAX® | -0.618% | 0.124% |
| iShares Nasdaq 100 | -2.524% | 0.616% |
| iShares Nikkei 225® | -1.006% | 6.561% |
| iShares S&P 500 | -1.088% | 1.848% |
Comments by HC_Wainwright for this prediction
In the thread Discuss Nektar Therapeutics
Nektar Therapeutics (NASDAQ: NKTR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.50 price target on the stock.
Ratings data for NKTR provided by MarketBeat
Stopped prediction by HC_Wainwright for Nektar Therapeutics
Nektar Therapeutics
Start price
Target price
Perf. (%)
€0.78
13.03.25
13.03.25
€5.97
13.03.26
13.03.26
-25.18%
06.06.25
06.06.25
Nektar Therapeutics
Start price
Target price
Perf. (%)
€0.97
13.01.25
13.01.25
€6.37
13.01.26
13.01.26
-40.23%
06.06.25
06.06.25
Nektar Therapeutics
Start price
Target price
Perf. (%)
€0.96
10.12.24
10.12.24
€6.18
10.12.25
10.12.25
-39.01%
06.06.25
06.06.25